olaparib
AstraZeneca's Lynparza Fails Phase II, Single-Arm Study in IDH-Mutant High-Grade Glioma
The trial did not meet its prespecified six-month progression-free survival rate, with only 11 of 35 patients reaching six months without progression.
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
Clovis' Rubraca Benefits BRCA1/2, PALB2-Mutated Pancreatic Cancer Patients as Maintenance Therapy
Premium
The study explored whether the PARP inhibitor benefitted patients with a wider range of mutations and pancreatic cancer subtypes than approved drugs.
NICE Recommends Lynparza, Avastin Combination in Ovarian Cancer Through Cancer Drugs Fund
While more data are collected, the CDF can provide the regimen to advanced, HRD-positive ovarian cancer patients after first-line platinum chemo and bevacizumab.
UK's NICE Does Not Recommend Lynparza for BRCA-Mutated Prostate Cancer
Lynparza is already approved to treat metastatic prostate cancer with BRCA1/2 mutations in Europe and the US.